금융 뉴스 허브
실시간 글로벌 금융 시장 뉴스 · 분석 · 인사이트
BREAKING주요 뉴스
British Pound wavers following overshot UK inflation data, higher public debt
The British Pound (GBP) wavered against the US Dollar (USD) on Wednesday following the release of st...
The Top 15 Stocks in the S&P 500 Are Now 47% of the Value. In 2000 Bubble, It Was 27%
The top 15 stocks now hold a record 46.7% of the S&P 500, far above the 27.2% share during the 2000 ...
Amplify COWS Covered Call ETF declares $0.2183 dividend
3 Reasons We’re Fans of SPX Technologies (SPXC)
Over the past six months, SPX Technologies’s stock price fell to $204.50. Shareholders have lost 9.1% of their capital, which is disappointing considering the S&P 500 has climbed by 11.6%. This might ...
September Is Historically a Slow Month for Stocks. Here's Why That Shouldn't Matter to Investors
Don't let the "September Effect" drive you out of the market.
Amplify Samsung SOFR ETF declares $0.3043 dividend
Amplify CWP Growth & Income ETF declares $0.2712 dividend
Amplify LQD Investment Grade 12% Target Income ETF declares $0.2402 dividend
Think the S&P 500 Is Too Expensive? These 2 ETFs Are Built for Exactly That
When S&P 500 valuations start making you nervous, abandoning the index entirely feels like an overcorrection. Two overlooked ETFs let you stay inside the same universe of companies while quietly tilti ...
Stock Market Midday, Aug. 28: Stocks Edge Higher on Fed's Clear Inflation Message
Fed officials signal more work ahead on inflation, keeping investors cautious as major indexes trade with modest gains, today, Aug. 28, 2026.
Update: US Equity Indexes Trade Mixed, Treasury Yields Jump After Warsh Reiterates Inflation Commitment
(Updates with index/price moves and geopolitical news from the first paragraph.) US equity indexe
Heartland Express (HTLD): Buy, Sell, or Hold Post Q2 Earnings?
Heartland Express has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 13% to $12.55 per share while the index has gained ...
Revolution Med risks weekly loss despite “transformative” FDA approval